

Rifaximin microbial resistance and its efficacy and safety as a secondary prophylaxis of hepatic encephalopathy in patients with hepatitis C virus-related cirrhosis

Doaa Hamed

Abstract

<https://pubmed.ncbi.nlm.nih.gov/34487412/>

International Journal of Clinical Practice 2021, November